Sleep in Older Adults: A Clinical Guide for Aging, Menopause, Pregnancy, Shift Work, and Jet Lag

How Sleep Architecture Changes After Age 60

Older adults spend less time in restorative slow-wave (N3) sleep and experience an earlier circadian phase, meaning they feel sleepy earlier and wake earlier than younger counterparts. The mean N3 percentage drops from roughly 20% in young adults to under 10% by the seventh decade, based on polysomnographic normative data reviewed in a 2004 meta-analysis of 65 studies published in Sleep (1). Sleep efficiency, the ratio of time asleep to time in bed, falls below 85% in a large share of community-dwelling adults over 65.

These changes are not purely a disease. They represent normal neurodegenerative shifts in the suprachiasmatic nucleus (SCN), the brain's circadian pacemaker. However, normal aging creates vulnerability. Comorbidities stack on top: nocturia, chronic pain, obstructive sleep apnea (OSA), restless legs syndrome (RLS), and depression all rise in prevalence after 60 and each independently fragments sleep.

Obstructive sleep apnea affects roughly 20 to 30% of adults over 65, compared with 5 to 10% of the general middle-aged population (2). Undiagnosed OSA in older adults is associated with a 2-to-3-fold increase in cardiovascular event risk. Standard treatment is CPAP; adherence at 4+ hours per night achieves clinically meaningful AHI reduction in the majority of older patients when combined with mask-fitting support.

Restless legs syndrome affects 10 to 35% of adults over 65. First-line pharmacotherapy per the 2016 American Academy of Sleep Medicine (AASM) guidelines is a low-dose dopamine agonist (pramipexole 0.125 to 0.5 mg or ropinirole 0.25 to 4 mg) or an alpha-2-delta calcium channel ligand (gabapentin enacarbil 600 mg) (3).

The HealthRX Sleep Protocol for Older Adults categorizes patients into three tiers before any pharmacologic intervention:

1. Rule out OSA with validated screening (STOP-BANG score of 3 or more triggers polysomnography referral).
2. Address modifiable contributors: nocturia workup, medication review (beta-blockers, diuretics, SSRIs all affect sleep architecture), and alcohol use.
3. Initiate CBT-I before any hypnotic prescription, consistent with the 2016 American College of Physicians (ACP) guideline recommending CBT-I as first-line therapy for chronic insomnia in adults (4).

Only patients who fail 6 weeks of structured CBT-I should be considered for pharmacotherapy.

CBT-I: The First-Line Treatment That Most Patients Never Receive

CBT-I outperforms sleep medication in head-to-head and long-term trials. The landmark meta-analysis by Morin and colleagues in JAMA Internal Medicine (2006, N=2,102) found CBT-I produced sleep-onset latency reductions of 54% versus 46% for pharmacotherapy, with CBT-I benefits persisting at 12-month follow-up while drug benefits regressed after discontinuation (5).

CBT-I combines sleep restriction therapy, stimulus control, cognitive restructuring, and sleep hygiene education. A standard protocol runs 6, 8 weekly sessions. Digital CBT-I programs (Sleepio, Somryst) have RCT support: a 2020 trial in JAMA Psychiatry (N=1,711) found internet-based CBT-I produced a 43% reduction in Insomnia Severity Index (ISI) scores compared with 17% for sleep hygiene control (6).

For older adults specifically, sleep restriction, the most potent CBT-I component, should be titrated cautiously. Restricting time in bed to under 5.5 hours in adults over 75 carries a small risk of cardiac arrhythmia exacerbation; start with a minimum time-in-bed window of 6 hours and advance in 15-minute increments weekly based on sleep efficiency above 85%.

Insomnia in Postmenopausal Women: Hormones, Vasomotor Events, and Treatment Options

Postmenopausal insomnia has a distinct mechanism. Vasomotor symptoms (hot flashes, night sweats) fragment sleep in up to 61% of peri- and postmenopausal women, according to the Study of Women's Health Across the Nation (SWAN) (7). Each vasomotor episode typically lasts 1 to 5 minutes and generates a cortical arousal. Women averaging 5 or more moderate-to-severe hot flashes per 24 hours lose, on average, 23 minutes of total sleep time per night compared with asymptomatic peers.

Menopausal hormone therapy (MHT) with estrogen addresses the root cause for many patients. A 2006 randomized controlled trial of oral estradiol 1 mg/day in postmenopausal women with vasomotor-driven insomnia (N=95) found significant reduction in nocturnal waking frequency at 12 weeks versus placebo (P<0.01) (8). The 2022 Menopause Society (NAMS) position statement affirms MHT as appropriate for healthy women under 60 and within 10 years of menopause onset, with the benefit-risk ratio favorable for sleep outcomes (9).

For women in whom MHT is contraindicated (active breast cancer, unexplained vaginal bleeding, active thromboembolism), evidence-based alternatives include:

• Low-dose paroxetine 7.5 mg (Brisdelle), the only non-hormonal FDA-approved treatment for menopausal vasomotor symptoms, which reduced hot flash frequency by 33 to 37% in the HARMONY trials (10).
• Fezolinetant (Veozah) 45 mg daily, a neurokinin 3 receptor antagonist approved by the FDA in May 2023, which reduced moderate-to-severe vasomotor symptom frequency by 53% in the SKYLIGHT 1 trial (N=501) at 12 weeks (11).
• CBT-I remains effective for the insomnia itself regardless of whether vasomotor symptoms are pharmacologically controlled.

Older postmenopausal women should also be screened for OSA. OSA prevalence in postmenopausal women rises to roughly 20%, approaching rates seen in men, compared with 6% in premenopausal women. Loss of progesterone, which has upper-airway muscle tone-protective effects, is the proposed mechanism (2).

Sleep Disorders in Pregnancy: Trimester-Specific Challenges

Pregnancy disrupts sleep at every trimester, but the drivers shift across gestation. Roughly 78% of pregnant women report sleep disturbances, with third-trimester prevalence the highest of any period (12).

First trimester changes include progesterone-driven somnolence and nocturia. Many women sleep 1 to 2 hours more per day but report lower sleep quality due to fragmentation. Second trimester often brings relative improvement. Third trimester introduces mechanical discomfort, heartburn, fetal movement, and leg cramps, all of which reduce sleep efficiency below 80% in most women.

OSA emerges or worsens during pregnancy. Gestational weight gain and upper-airway edema increase OSA risk, and the condition is associated with gestational hypertension, preeclampsia, and fetal growth restriction. A 2014 prospective cohort study (N=3,132) in the American Journal of Obstetrics and Gynecology found that sleep-disordered breathing in pregnancy was associated with a 2.3-fold increased risk of gestational diabetes (13).

Pharmacologic sleep aids are heavily restricted in pregnancy:

• Benzodiazepines and Z-drugs (zolpidem, eszopiclone) are FDA Pregnancy Category not recommended; limited safety data and potential neonatal withdrawal effects.
• Low-dose doxylamine 10 mg combined with pyridoxine 10 mg (Diclegis/Bonjesta, approved for nausea) has a longer safety record in pregnancy but is used off-label for sleep.
• Diphenhydramine 25 mg has been used for short-term sleep in pregnancy, with no strong teratogenic signal in observational data, but tolerance develops within 3, 5 nights.
• Melatonin is not FDA-approved for sleep disorders in pregnancy. Animal data suggest fetal receptors are melatonin-sensitive; human safety trials are lacking. Advise caution.

Positional therapy for third-trimester women with OSA-level AHI is the safest first intervention. Left lateral positioning reduces AHI by a mean of 31% compared with supine sleep in pregnant patients per a 2019 review (14). CPAP is safe and recommended for pregnant women with confirmed moderate-to-severe OSA (AHI 15 or above).

The ACP guideline note on CBT-I applies here too: behavioral sleep interventions remain safe throughout pregnancy and carry no fetal risk. "We recommend all adult patients receive CBT-I as the initial treatment for chronic insomnia disorder," states the 2016 ACP Clinical Practice Guideline (4).

Shift Work Sleep Disorder: Clinical Criteria and Treatment Protocol

Shift work sleep disorder (SWSD) is a circadian rhythm disorder defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3) as insomnia or excessive sleepiness coinciding with a recurring work schedule that overlaps with the habitual sleep period, sustained for at least 3 months. Between 10% and 38% of shift workers meet diagnostic criteria (15).

The health consequences extend well beyond fatigue. A 2021 meta-analysis in BMJ of 22 prospective cohort studies (N=226,652) found rotating shift work associated with a 17% increased risk of type 2 diabetes and a 23% increased cardiovascular disease risk versus daytime workers (16). Older shift workers carry an amplified risk because age-related SCN vulnerability compounds circadian misalignment.

Clinical management follows a three-track approach:

Track 1: Light therapy. Appropriately timed bright light (10,000 lux for 30 minutes) immediately after arriving home from a night shift delays circadian phase and improves daytime sleep. Wearing dark glasses during the morning commute home blunts inadvertent phase-advancing light exposure.

Track 2: Strategic melatonin. Taking melatonin 0.5 mg 30 minutes before the desired daytime sleep onset (not 5 mg, which saturates melatonin receptors without additional benefit) improves sleep onset latency in shift workers by a mean of 17 minutes per a Cochrane review (Sack et al., 2007) (17).

Track 3: Pharmacotherapy for wakefulness. Modafinil 200 mg (Schedule IV) is the only FDA-approved drug for SWSD, indicated to promote wakefulness during the night shift. In the key approval trial (N=278), modafinil reduced ESS sleepiness scores by 2.3 points versus 0.9 for placebo at 12 weeks (P<0.001) (18). Armodafinil 150 mg is an approved alternative with a longer half-life, useful for workers with extended shifts of 12 hours or more.

Older adults and those with cardiovascular comorbidities require a cardiology consultation before starting wakefulness agents, as both modafinil and armodafinil raise blood pressure by an average of 2 to 3 mmHg in clinical trials.

Jet Lag: Pathophysiology and Evidence-Based Recovery Protocols

Jet lag is a transient circadian disorder caused by rapid travel across two or more time zones. The core problem: the SCN re-entrains to local time at roughly 1 hour per day eastward and 1.5 hours per day westward, so a traveler crossing 6 time zones eastward takes 5 to 6 days to fully re-entrain without intervention (19).

Eastward travel causes greater difficulty because it requires phase advancement (shifting the clock earlier), which the human circadian system does less readily than phase delay. Symptoms include sleep-onset insomnia at the destination, daytime fatigue, gastrointestinal disruption, and reduced cognitive performance. A 2003 review in The Lancet noted that cognitive errors peak during the first two days after eastward transmeridian travel and are worst between 3 and 7 a.m. local destination time (20).

Melatonin for jet lag. A 2002 Cochrane review of 10 randomized trials found melatonin 0.5 to 5 mg taken at destination bedtime reduced jet lag severity by a clinically meaningful margin when crossing 5 or more time zones. The 0.5 mg dose produced equivalent re-entrainment to 5 mg but with fewer side effects (morning grogginess, headache) (21). For eastward travel of 5 or more zones, begin melatonin 3 mg the night before departure and continue at destination bedtime for 4 nights.

Pre-flight circadian shifting. Shifting sleep/wake times by 1 to 2 hours in the direction of travel starting 3 days before departure reduces jet lag severity at the destination. Eastward travelers advance sleep by 1 hour per night; westward travelers delay by 1 hour per night.

Light exposure timing at destination. Eastward travelers should seek bright morning light (7, 10 a.m.) at the destination to advance phase. Avoid light exposure between 10 p.m. and 2 a.m. local time for the first 2 nights. Westward travelers benefit from evening light (6, 9 p.m. local) to delay phase.

Short-acting hypnotics for acute jet lag. Zolpidem 5 mg (or 2.5 mg for adults over 65) taken at destination bedtime for up to 3 nights manages sleep-onset insomnia acutely. The 2019 FDA safety communication updated black-box labeling for zolpidem, eszopiclone, and zaleplon warning of next-day impaired driving and complex sleep behaviors; older adults are most vulnerable (22). Use the lowest effective dose and advise 8 hours of available sleep time before any driving.

The AASM's 2007 clinical practice parameter for jet lag states: "Melatonin is effective for reducing the overall symptoms of jet lag and is recommended for use in jet lag disorder" (19).

Pharmacotherapy Cautions in Older Adults: The Beers Criteria and Z-Drug Risk

The 2023 American Geriatrics Society Beers Criteria explicitly lists benzodiazepines, Z-drugs (zolpidem, eszopiclone, zaleplon), and first-generation antihistamines (diphenhydramine, doxylamine) as medications to avoid in adults aged 65 and older because of falls, hip fractures, and cognitive impairment risk (23). "These agents should be avoided in older adults due to increased sensitivity to CNS effects and increased risk of motor vehicle accidents, falls, and fractures," reads the 2023 AGS Beers Criteria summary.

When pharmacotherapy is genuinely needed in older adults after CBT-I failure, safer options include:

• Low-dose doxepin 3 to 6 mg (Silenor), FDA-approved specifically for sleep maintenance insomnia, with a mechanism limited to histamine H1 receptor blockade at these doses and minimal next-day sedation data in adults 65+ (24).
• Suvorexant 10 mg (Belsomra), an orexin receptor antagonist, starting at 5 mg for older adults. The SUNSET trial (N=285 adults 65+, 12 months) found suvorexant 10 mg improved total sleep time by 22 minutes versus placebo without significant next-day impairment at 12 months (25).
• Lemborexant 5 mg (Dayvigo), a second-generation dual orexin receptor antagonist, with a half-life of 17 to 19 hours and no dose adjustment required for renal impairment.

Ramelteon 8 mg, a melatonin receptor agonist, is Beers Criteria-safe for older adults. It does not impair next-day performance and carries no dependence potential, but its effect size on sleep latency averages only 7 to 8 minutes versus placebo, which is modest for patients with significant insomnia (26).